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INTRODUCTION
Breast cancer is one of the most common malignan-
cies diagnosed in women and comprises about 18% of all 
female cancers.1 Surgery is the primary modality for the 
treatment of breast cancer, depending on tumor stage.2 
An increasing number of breast cancer patients are opting 
for mastectomy with reconstruction for treatment.
Postmastectomy reconstruction can surgically restore 
the shape of the breast and provide breast cancer patients 
with psychological benefits.3,4 There are 2 types of postmas-
tectomy reconstructions: autologous tissue flap and tissue 
expander/implant. Although autologous tissue provides 
the most lasting and natural outcomes, implant-based 
breast reconstruction is the more popular procedure, 
accounting for about 80% of postmastectomy reconstruc-
tions.5,6 Breast reconstruction can be divided by timing into 
immediate breast reconstruction (IBR) and delayed breast 
reconstruction (DBR). IBR, compared to DBR, offers a 
native inframammary fold and a pliable skin envelope for 
a more natural appearance.7 IBR also reduces psychologi-
cal impact on patients8 and thus may be favored by some 
patients. However, compared to DBR, IBR is associated 
with greater risk of surgical site infection (SSI).9,10
SSI is defined as infection of the superficial incision, 
organ, and/or space after surgery. Accordingly, there are 
3 categories of SSI: superficial incisional SSI, deep inci-
sional SSI, and organ/space SSI.11 The rate of SSI is strongly 
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Background: The risk of surgical site infection (SSI) for breast surgery in patients 
without additional risk factors is low, below 5%. Evidence shows the risk of SSI 
is significantly elevated in patients undergoing immediate breast reconstruction 
(IBR). However, there is no consensus regarding the use of extended antibiotic 
prophylaxis. We aim to determine the effect of extended antibiotic prophylaxis on 
the incidence of SSI after IBR.
Methods: PubMed and Scopus were searched by 2 independent reviewers. Data 
abstracted included types of study, basic characteristics, detailed antibiotic prophylaxis 
information, SSI event, and other secondary outcomes. We calculated the risk ratio 
(RR) and 95% confidence interval (CI) for each study and used a random-effects 
model to estimate the results. Study quality, bias, and heterogeneity were also analyzed.
Results: A total of 11 studies (15,966 mastectomy procedures) were included. We 
found an overall 5.99% SSI rate in our population. Three studies comparing topi-
cal antibiotics with no topical antibiotics demonstrated statistical significance (RR 
= 0.26, 95% CI: 0.12–0.60, P = 0.001), whereas 8 studies comparing extended sys-
temic antibiotics with standard of care found no statistical significance (RR = 0.80, 
95% CI: 0.60–1.08, P = 0.13).
Conclusions: In the setting of IBR following mastectomy, there is insufficient evi-
dence for the use of extended prophylactic antibiotics to reduce SSI rates. Well-
designed randomized controlled trials in patients undergoing IBR should be 
conducted to determine the appropriate regimen and/or duration of prophy-
lactic antibiotics on SSI outcomes. (Plast Reconstr Surg Glob Open 2020;8:e2613;  
doi: 10.1097/GOX.0000000000002613; Published online 27 January 2020.)
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associated with the type of surgical wound. The Centers for 
Disease Control (CDC) published a guideline in 1985,12 
which classified surgical wounds into clean, clean/con-
taminated, contaminated, and dirty, with the SSI rate of 
1%–5%, 3%–11%, 10%–17%, and over 27%, respectively.13 
The occurrence of SSI can impact the postoperative recov-
ery process and result in extra cost and rate of hospital 
readmissions.
Breast surgeries are classically categorized as clean,14 
and according to the CDC and the Surgical Care 
Improvement Project, for breast surgical procedures, 
antibiotics should be discontinued within 24 hours after 
surgery.12 However, among breast surgeries, IBR with a 
tissue expander/implant is associated with higher SSI, 
with the average SSI rate ranging from 5% to as high as 
35%.10,15,16
In the setting of IBR, several studies supported the use 
of extended prophylactic antibiotics to prevent SSI,17–19 
but others stated that extended antibiotic usage could 
lead to systemic side effects and the development of 
resistant organisms.20–22 Thus, there is still no consensus 
regarding the extended usage, regimens, and timing of 
prophylactic antibiotics for mastectomy with IBR. This 
meta-analysis aims to determine the efficacy and safety 
of extended prophylactic antibiotics on SSI after mastec-
tomy with IBR.
PATIENTS AND METHODS
Search Strategy
Our study followed guidelines published by the Centre 
for Reviews and Dissemination (CRD) and the Cochrane 
Collaboration and the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses criteria .23,24 A 
protocol for this systematic review was registered using 
Prospero (CRD42019127536).
We included patients undergoing mastectomy with 
IBR, or mixed types (IBR and DBR) if the study had sepa-
rate outcomes for IBR and DBR groups. Both randomized 
controlled trials (RCTs) and observational studies were 
included. Studies that compare pre-, peri-, postoperative 
extended prophylactic antibiotics with standard of care 
were included. Studies with no comparison group were 
excluded.
Two reviewers independently assessed the title and 
abstract of articles identified by the search described 
earlier. Two reviewers applied the inclusion and exclu-
sion criteria, and disagreements were resolved by read-
ing the full text. A third reviewer examined the article 
and made the final decision if still undecided. The 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses flowchart diagram of literature retrieval is 
shown in Fig. 1.
Data Extraction
Two reviewers independently extracted the data. Data 
were collected from each study: the first author, publi-
cation year, study design, number of procedures, type 
of IBR, antibiotics (ie, regimen name, dose, duration of 
treatment), and outcomes.
Quality Assessment for Included Studies
Two reviewers independently assessed the study qual-
ity using the Newcastle–Ottawa Scale.25 The Newcastle–
Ottawa Scale is used to evaluate non-RCTs, with 1 version 
for case–control studies and the other for cohort studies. 
Both versions of the scale consist of 8 multiple-choice ques-
tions that address subject selection and comparability (of 
cases and controls in case–control studies and of cohorts 
in cohort studies) and the assessment of the outcome (in 
case–control studies) or exposure (in cohort studies).
Dealing with Missing Data
For those articles which met inclusion criteria but had 
incomplete data (ie, missing type of standard of care of com-
parison group, or no details of antibiotic use of extended 
antibiotics group), we emailed the corresponding author of 
that article. If corresponding authors did not respond after 
3 weeks, the article was labeled as having incomplete data, 
and this would be mentioned in the results section.
Outcome Measures and Data Synthesis
All statistical analyses were performed by Review 
Manager V.5.3 (The Cochrane Collaboration, Software 
Update, Oxford, UK). We calculated the risk ratio (RR) at 
95% confidence interval (CI) for each study, weighted by 
the number of events in each study. Statistical significance 
was defined as 2-tailed alpha < 0.05. Forest plots were gen-
erated for graphical presentations for clinical outcomes, 
and we used I2 statistics to define the heterogeneity of 
each study. Mantel-Haenszel method was used to conduct 
meta-analysis, and because I2 was >50%, we used the ran-
dom-effects model instead of the fixed-effects model. We 
did subgroup analyses where the data were applicable.
Assessment of Heterogeneity
We assessed the heterogeneity between study results 
using the I2 statistics. The result is a percentage of total 
variation among studies due to heterogeneity. I2 is com-
monly divided into 3 categories—low, moderate, and high, 
with upper limits of 25%, 50%, and 75%, respectively.26
Sensitivity Analysis
We assessed the influence of a single study on the overall 
effect by sequentially removing 1 study at a time to test the 
robustness of the pooled results to further verify whether 
any study had an excessive influence on the overall results.
RESULTS
Results of the Search
A total of 597 articles were identified, of which 297 
articles were excluded as they were ineligible publication 
types. After initial screening of the remaining 300 origi-
nal articles, we further excluded 289 articles because they 
were irrelevant to our study topic or had incomplete data. 
The details of the search strategy are shown in Fig. 1.
Characteristics of Included Studies
A total of 11 studies (15,966 mastectomy procedures) 
were included, 10,688 in the extended antibiotics arm and 
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5,278 in the comparison arm. One was an RCT,21 and 10 
studies17–20,22,27–31 were retrospective studies with 1 matched 
cohort study.31 The studies were published between 2009 
and 2018, with sample sizes ranging from 112 to 7,443 
mastectomies. The main characteristics of all  11 studies 
are presented in Table 1.
Type of Procedures
All procedures were unilateral or bilateral mastectomy 
with IBR. Immediate breast implant, tissue expander, and 
autologous flap (including latissimus dorsi flap and sub-
pectoral flap) placement were described in 7, 3, and 2 
studies, respectively.
Timing and Types of Antibiotics
Eight studies evaluated the usage of extended postop-
erative systemic prophylactic antibiotics compared to stan-
dard of care, where antibiotics are discontinued within 24 
hours after breast surgery.12 However, the duration and 
types of antibiotics used vary between studies. In 5 of 8 
studies,17,18,21,22,31 all patients were given pre- or periopera-
tive antibiotics as baseline treatment, whereas the other 3 
studies20,29,30 had incomplete data on antibiotic usage in 
their comparison groups. The study design was also differ-
ent. Of the 8 studies, 1 study was an RCT, 2 studies were 
claims databases with a large sample size, and 5 studies 
were single-site retrospective studies.
Three studies evaluated the usage of postoperative 
topical antibiotics compared to no postoperative topi-
cal antibiotics. Two articles19,28 focused on the usage of 
topical mupirocin ointment and irrigation with both the 
extended antibiotics group and comparison arm using the 
same pre-/ peri- and postoperative antibiotics. The third 
article27 used a novel antibiotic bead compared to com-
parison, where both arms had the same preoperative and 
irrigation antibiotics.
Synthesis of Results
Incidence of SSI
We found an overall average SSI rate of 5.99% in mas-
tectomy procedures. Heterogeneity within the interventions 
used in the study prevented pooling of all the studies for anal-
ysis. Analysis of 8 studies comparing extended systemic anti-
biotics with standard of care found no statistical significance 
(RR = 0.80, 95% CI: 0.60–1.07, P = 0.13) (Fig. 2); as 1 RCT and 
Fig. 1. the PriSMa diagram of literature retrieved. PriSMa, Preferred reporting items for Systematic reviews and 
Meta-analyses.
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2 claims database studies are in the group of 8 studies, we also 
conducted other sensitivity analysis to check whether these 
studies may have affected the results (see further “Sensitivity 
Analysis” section). For the topical antibiotics group, analysis 
of the 3 studies comparing topical antibiotics with no topical 
antibiotics demonstrated statistically significant effect of anti-
biotics on reducing the incidence of SSI (RR = 0.26, 95% CI: 
0.12–0.60, P = 0.001) (Fig. 3) However, this statistical signifi-
cance has to be interpreted with caution, as more research is 
needed to confirm the findings. The use of topical mupirocin 
ointment and the use of novel antibiotic beads may not be 
generalizable to many other centers’ experiences.
Wound Complications
Wound complications included hematoma, wound 
dehiscence, seroma, hematoma, and mastectomy flap necro-
sis. Four17,19,29,30 studies measured the incidence of wound 
complications, with 9,789 mastectomies on extended pro-
phylactic antibiotics and 4,220 mastectomies on standard 
of care. Analysis of the 4 studies comparing extended pro-
phylactic antibiotics with standard of care found no statisti-
cally significant effect on reducing the incidence of wound 
complications (RR = 0.89, 95% CI: 0.78–1.03, P = 0.12). The 
result is presented in Supplemental Digital Content 1, which 
displays a forest plot of wound complications subgroup anal-
ysis, http://links.lww.com/PRSGO/B293).
Hospital Readmission
Only 1 study measured the incidence of hospital read-
mission, with 6,049 mastectomies on extended prophy-
lactic antibiotics and 1,349 mastectomies on standard of 
care. Analysis of the study comparing extended prophy-
lactic antibiotics with standard of care found no statistical 
significance in reducing the rate of hospital readmission 
(RR = 1.22, 95% CI: 0.85–1.74, P = 0.28). The result is pre-
sented in Supplemental Digital Content 2, which displays 
forest plot of readmission subgroup analysis, http://links.
lww.com/PRSGO/B294).
Table 1. Characteristics of Included Studies (n = 11)
Study Study Design
Type of  
Reconstruction
No.  
Operations
Intervention 
Group  
Antibiotics
Intervention  
Group SSI (%)
Control Group 
Antibiotics
Control Group 
SSI (%)
Avashia et al17 Retrospective IBR TE 138
Postoperative  
> 24 h 8/119 (6.7%) Standard of care 6/19 (31.6%)
Hunsicker et al19 Retrospective IBR implant 535 Postoperative 
irrigation  
for 96 h
6/316 (1.9%) Standard of care + 
irrigation once
14/219 (6.4%)
Clayton et al18 Retrospective IBR implant 250 Postoperative  
> 24 h
21/116 (18.1%) Standard of care 46/134 
(34.3%)
Goh et al20 Retrospective IBR TE, 
latissimus dorsi, 
subpectoral
240 Postoperative  
> 24 h
12/145 (8.3%) Standard of care 2/95 (2.1%)
Kenna et al27 Retrospective IBR implant 127 Irrigation + 
antibiotic beads
1/68 (1.47%) Standard of care 7/59 (11.86%)
McCullough  
et al22
Retrospective IBR implant 378 Postoperative  
> 24 h
24/200 (12%) Standard of care 24/178 
(13/5%)
Murray et al28 Retrospective IBR TE 200 Topical ointment 0/23 (0%) Standard of care 10/177 
(5.65%)
Olsen et al29 Retrospective IBR implant,  
flap, both
5,938 Postoperative  
> 24 h
240/3,305 
(7.26%)
Standard of care 213/2,633 
(8.09%)
Phillips et al21 RCT IBR implant 112 Postoperative  
> 24 h
11/50 (22%) Standard of care 12/62 
(19.35%)
Ranganathan  
et al30
Retrospective IBR implant 7,443 Postoperative  
> 24 h
166/6,049 
(5.26%)
Standard of care 41/1,394 
(5.45%)
Townley et al31 Retrospective IBR implant 605 Postoperative  
> 24 h
9/297 (3.03%) Standard of care 11/308 (3.6%)
TE, tissue expander.
Fig. 2. Forest plot of studies that compared systemic antibiotics to standard of care (n = 8). SOc, standard of care. rr, risk ratio. M-H, 
Mantel-Haenszel.
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Quality Assessment for Included Studies
We created a quality assessment figure based on the 
Risk of Bias Tool found in the Cochrane Handbook for 
Systemic Reviews of Interventions,32 and we presented the 
percentages of risk in each of the 9 domains. High-quality 
responses were marked “low risk.” The result is shown in 
Supplemental Digital Content 3, which displays risk of 
bias, http://links.lww.com/PRSGO/B295.
Sensitivity Analysis and Publication Bias
Funnel plot analysis disclosed no asymmetry around 
the axis, which means that publication bias was not 
detected (Fig. 4). No significant results were identified in 
the “leave one out” sensitivity test.
Further Sensitivity Analysis to Understand Heterogeneity 
across Studies
As there were substantial differences in the types of 
studies within the 8 studies that investigated extended 
antibiotics on SSI, we conducted 2 further analyses. 
First, we noted that 2 studies using claims database had 
88.5% of the weight (Fig. 2). We analyzed extended sys-
temic antibiotics with and without the 2 claims database 
studies, resulting in 8 and 6 studies (Fig. 2) [see figure, 
Supplemental Digital Content 5, which displays a forest 
plot of extended systemic prophylactic antibiotics (with-
out 2 claims databases), http://links.lww.com/PRSGO/
B297]. In Fig. 2, RR was 0.80 (95% CI: 0.60–1.07, I2 = 61%). 
In Supplemental Digital Content 5, which displays a forest 
plot of extended systemic prophylactic antibiotics (with-
out 2 claims databases) [http://links.lww.com/PRSGO/
B297], RR was 0.93 (CI: 0.49–1.80, I2 = 79%). Both analyses 
showed no overall significance, but statistical heterogene-
ity increased slightly. We conclude that claims databases, 
even with their larger sample sizes, did not greatly alter 
the RR in this instance. We also note that a random-effects 
model is more accurate than a fixed-effects model due to 
the heterogeneity of the studies included.
There was 1 RCT among our included studies, and we 
were interested in its effect (or lack thereof) on the meta-
analysis. Taken alone, the RCT reported no differences 
between 24-hour antibiotics or extended antibiotics (until 
drain removed), with an RR of 1.18 (95% CI: 0.47–2.95). 
We conducted an analysis of extended systemic antibiot-
ics with and without this RCT, resulting in 8 and 7 stud-
ies [Fig. 2; also see figure, Supplemental Digital Content 
4, which displays a forest plot of extended systemic pro-
phylactic antibiotics (without RCT study), http://links.
lww.com/PRSGO/B296]. In Fig. 2, RR was 0.80 (95% CI: 
0.60–1.07, I2 = 61%). The weight of the RCT was 0.7%. 
In Supplemental Digital Content 4, which displays a forest 
plot of extended systemic prophylactic antibiotics (with-
out RCT study) [http://links.lww.com/PRSGO/B296], 
RR was 0.77 (95% CI: 0.56–1.06, I2 = 65%). Overall, the 
RCT did not change the results of the 8 studies. We note 
that given the nature of the study, theoretically the RCT 
should have been given more weight, but our predefined 
statistical method did not provide allowances for ad hoc 
increases in statistical weight.
DISCUSSION
For patients who are opting for mastectomy with recon-
struction as treatment, IBR, especially implant-based IBR, 
has become a common procedure to restore the shape of 
the breast and improve psychological well-being.33 Breast 
surgery is historically thought of as a “clean” procedure,14 
and for clean surgical procedures, the CDC calls for the 
discontinuation of perioperative prophylactic antibiotics 
within 24 hours.12 In recent years, some have advocated 
breast surgeries as “clean-contaminated” procedures,34,35 
noting the breast microbiome36,37 and bacteria presence on 
normal breast implants,38 and of contamination of breast 
implants even when precautions are taken.39 However, this 
may be more complicated than applying a blanket label 
for all breast surgeries, because the SSI rates after differ-
ent breast surgeries have varied widely in the published 
literature, ranging from 0.8% to 26%.40,41 Among all types 
of procedures, mastectomy with implant-based IBR has a 
2-fold increase in SSI incidence compared with mastectomy 
Fig. 3. Forest plot of studies that compared topical antibiotics to standard of care (n = 3). SOc, standard of care. rr, risk ratio. M-H, 
Mantel-Haenszel.
Fig. 4. Funnel plot of included studies (n = 11). Se, standard error. 
rr, risk ratio.
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alone.42 Therefore, antibiotics are usually prescribed for an 
extended duration after mastectomy with IBR even though 
there is a lack of clinical evidence. Such practice has been 
prone to criticism by infection control officers and others 
who quote data from studies suggesting no corresponding 
decrease in rates of postoperative infection despite increas-
ing use of prophylactic antibiotics.16,43–45 During that time, 
a center implemented changes to not provide postop-
erative prophylactic antibiotics for breast reconstruction 
(from previous practice of giving postoperative antibiotics 
until drains were removed). They reported that this is asso-
ciated with an increased risk of infection.18 The group then 
proposed an RCT to test out the optimal duration of post-
operative antibiotics. Amid the controversy, there is still no 
consensus for reconstructive breast surgeries, including 
postmastectomy implant-based IBR.
Our study aimed to examine the correlation of extended 
antibiotic prophylaxis (>24 hours postoperatively) and 
the incidence of SSI after IBR. The average SSI rate of 
our study population was 5.99%, ranging from 2.83% to 
26.2%. Our meta-analysis found that extended postopera-
tive systemic antibiotics had no significant effect on reduc-
ing the incidence of SSI. According to our protocol, we 
initially aimed to pool all the studies in a forest plot, but 
given the heterogeneity of the studies included, this was 
not statistically or clinically appropriate. Further subgroup 
analysis demonstrated that extended antibiotic prophylaxis 
showed no significant effect on reducing the incidence of 
wound complications and hospital readmission.
This is the first meta-analysis focusing on the effects 
of using extended prophylactic antibiotics for postmastec-
tomy IBR in both topical and systemic antibiotics groups. 
However, there are several limitations in our meta-analysis, 
which are mostly related to the studies that were analyzed. 
First, there are missing data in some of the studies. Three 
out of the 11 studies lacked adequate descriptions of their 
antibiotic protocols for the comparison groups and most 
studies lacked antibiotic protocols and a defined time of 
discontinuation.
The second limitation was the heterogeneity of the 
included studies. As we mentioned earlier, we divided I2 
into 3 categories—low, moderate, and high, with upper 
limits of 25%, 50%, and 75%. The average I2 of our studies 
is around 60%. According to a previous review, a quarter 
of meta-analyses has I2 values over 50%, and quantification 
of heterogeneity is only 1 component of a wider evalua-
tion of variability among different studies.26 Thus, meta-
analysts must also consider the clinical applications of the 
observed level of inconsistency across different studies. In 
particular for our studies, antibiotics were not used uni-
formly in terms of regimens, timing, dosing, and duration. 
There was no indication that there was any standardiza-
tion of what constituted an SSI in the included articles. 
Redness, fever, requirement for intraoperative irrigation, 
requirement for removal of the implant or expander, and 
a combination of the following could technically consti-
tute SSI.46 Thus, having clarity of what makes an SSI would 
be very important for any prospectively designed study. 
Disagreement on what constitutes an SSI is a commonly 
encountered problem when comparing articles discussing 
infection rates, as it may be field specific. We would like 
to engage stakeholders and experts in the area of breast 
reconstruction to potentially form a consensus for pro-
spective studies that will improve evidence-based practices.
The third limitation is the type of studies included. 
Ten of 11 studies were retrospective studies. Since there 
was only 1 RCT conducted within the included studies, 
more well-designed RCTs should be conducted to dem-
onstrate the effect of different regimens of prophylactic 
antibiotics on the SSI rate of IBR. Appropriate prophylac-
tic antibiotic protocols should be tested. Finally, a better 
reporting system of the types of SSI, antibiotic regime/
dosage/duration, and other complications should be used 
for future studies.
Future Directions
Given the paucity of prospective studies on this 
important topic, well-designed studies are sorely needed. 
However, there are many prior considerations that go 
into a well-designed prospective study for this particular 
question. Although we try not to prescribe particular rules 
here, the following questions (among others) are impor-
tant to consider. Should patients with tissue necrosis be 
excluded? Should cases done by surgeons who leave com-
pletely different flap thicknesses be grouped together? 
Should reconstructions going under the muscle be com-
pared to reconstructions done above the muscle? Should 
small areas of necrosis count the same as larger areas? 
Should the experience of the plastic surgeon be assessed? 
Should drain removal be based on drainage volume or 
based on duration, and if so, how much? Should patients 
who are discharged from hospital with a drain be grouped 
separately? It has been noted that these factors, while 
important in predicting SSI, are never available from ret-
rospective chart reviews. Importantly, regarding antibiotic 
duration, the timepoints of antibiotics for 24 hours only, 
antibiotics until drain removal (which can vary signifi-
cantly), and antibiotics for a certain duration after drain 
removal are essential to study and compare. Even if the 
sample size is relatively low, such well-controlled prospec-
tive studies will be valued. We rally surgeons in this field to 
consider starting prospective studies on this.
CONCLUSIONS
From our systematic review and meta-analysis, we con-
clude that, at this point, in part due to the lack of large 
prospective studies and in part due to the heterogeneity 
of interventions, there are insufficient data to suggest that 
extended antibiotics reduce the risk of SSI in patients 
undergoing mastectomy with IBR. Moreover, broad-spec-
trum antibiotics may significantly influence the normal 
gastrointestinal flora and lead to unfavorable clinical 
consequences, such as Clostridium difficile–related pseudo-
membranous colitis and antibiotic resistance. Therefore, 
we appeal for RCTs that test if there is improved efficacy 
and safety of extended prophylactic antibiotics on IBR. In 
particular, focus should be put on the choice of antibiotic 
regimens, the treatment duration, and a standardized 
clinical criterion for SSI evaluation.
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